Avadel Pharmaceuticals Plc Sponsored ADR AVDL 深 滬
交易中 09-10 11:32:48 美东时间
15.85
+0.260
+1.67%
華盛通- 最 高15.98
- 今 開15.53
- 成交量 29.77万股
- 最 低 15.45
- 昨 收 15.59
- 總市值 15.39亿
- 52周最高 16.66
- 市盈率 靜 --
- 換手率 0.31%
- 52周最低 6.38
- 委 比 -55.91%
- 總股本 9709.76万
- 歷史最高 19.09
- 量 比 0.55
- 振 幅 3.40%
- 歷史最低 1.03
- 每 手 1
- 風險率 1.97%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Wells Fargo Initiates Coverage On Avadel Pharmaceuticals with Equal-Weight Rating, Announces Price Target of $16
Wells Fargo analyst Benjamin Burnett initiates coverage on Avadel Pharmaceuticals (NASDAQ:AVDL) with a Equal-Weight rating and announces Price Target of $16.
09-03 20:37
Avadel Pharmaceuticals Strengthens Sleep Medicine Portfolio with Exclusive License of Valiloxybate from XWPharma Ltd
Avadel Pharmaceuticals has entered into an exclusive global license agreement with XWPharma to develop and commercialize valiloxybate, a once-at-bedtime, salt-free, and artificial sweetener-free GABA receptor agonist for treating narcolepsy and idiopathic hypersomnia. Under the agreement, XWPharma receives a $20 million upfront payment, milestone payments, and royalties. Avadel plans to initiate pharmacokinetic studies in Q4 2025, with a pivotal ...
09-03 20:30
Avadel Pharmaceuticals to Present at Upcoming Investor Conferences
Avadel Pharmaceuticals announced that its management will participate in three upcoming investor conferences in September 2025. Details include: 2025 Wells Fargo Healthcare Conference on September 5 at 11:00 a.m. ET, Morgan Stanley 23rd Global Healthcare Conference on September 9 at 1:05 p.m. ET, and H.C. Wainwright 27th Global Investment Conference on September 10 at 9:30 a.m. ET. Webcasts and recordings will be available on Avadel’s Investor Re...
08-29 12:00
UBS Maintains Buy on Avadel Pharmaceuticals, Raises Price Target to $20
UBS analyst Ashwani Verma maintains Avadel Pharmaceuticals (NASDAQ:AVDL) with a Buy and raises the price target from $13 to $20.
08-21 21:37
Avadel Pharmaceuticals shares are trading higher after the company reported better-than-expected Q2 financial results and raised its FY25 sales guidance above estimates.
Avadel Pharmaceuticals shares are trading higher after the company reported bet...
08-07 21:01
Avadel Pharmaceuticals Raises FY2025 Sales Guidance from $255.000M-$265.000M to $265.000M-$275.000M vs $260.077M Est
Avadel Pharmaceuticals (NASDAQ:AVDL) raises FY2025 sales outlook from $255.000 million-$265.000 million to $265.000 million-$275.000 million vs $260.077 million estimate.
08-07 19:11
Avadel Pharmaceuticals Q2 EPS $0.10 Beats $0.03 Estimate, Sales $68.129M Beat $61.457M Estimate
Avadel Pharmaceuticals (NASDAQ:AVDL) reported quarterly earnings of $0.10 per share which beat the analyst consensus estimate of $0.03 by 222.58 percent. This is a 171.43 percent increase over losses of $(0.14) per share
08-07 19:03
Earnings Scheduled For August 7, 2025
Companies Reporting Before The Bell • GoHealth (NASDAQ:GOCO) is estimated to re...
08-07 16:33
Avadel Pharmaceuticals to Provide a Corporate Update and Report Second Quarter 2025 Financial Results on August 7
Avadel Pharmaceuticals will host a conference call on August 7, 2025, at 8:30 a.m. ET to discuss its second-quarter 2025 financial results. A live webcast and replay will be available on the company’s website, www.avadel.com. Participants can register for the call in advance. The company operates in the biopharmaceutical sector and markets LUMRYZ™, its FDA-approved treatment for narcolepsy.
07-31 12:00
HC Wainwright & Co. Assumes Avadel Pharmaceuticals at Buy, Announces Price Target of $22
HC Wainwright & Co. analyst Raghuram Selvaraju assumes Avadel Pharmaceuticals (NASDAQ:AVDL) with a Buy rating and announces Price Target of $22.
07-18 18:36
